CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Protara Therapeutics, Inc. - TARA CFD

    1.58
    3.27%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Protara Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.53
    Open* 1.65
    1-Year Change* -45.54%
    Day's Range* 1.58 - 1.67
    52 wk Range 1.12-4.18
    Average Volume (10 days) 45.15K
    Average Volume (3 months) 618.99K
    Market Cap 12.96M
    P/E Ratio -100.00K
    Shares Outstanding 11.36M
    Revenue N/A
    EPS -6.13
    Dividend (Yield %) N/A
    Beta 1.07
    Next Earnings Date Mar 6, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 1.53 0.16 11.68% 1.37 1.59 1.37
    Dec 7, 2023 1.35 -0.05 -3.57% 1.40 1.41 1.35
    Dec 6, 2023 1.39 0.03 2.21% 1.36 1.39 1.35
    Dec 5, 2023 1.36 -0.03 -2.16% 1.39 1.43 1.32
    Dec 4, 2023 1.37 -0.04 -2.84% 1.41 1.44 1.34
    Dec 1, 2023 1.40 0.02 1.45% 1.38 1.43 1.37
    Nov 30, 2023 1.38 0.02 1.47% 1.36 1.49 1.24
    Nov 29, 2023 1.47 0.06 4.26% 1.41 1.60 1.41
    Nov 28, 2023 1.39 0.11 8.59% 1.28 1.39 1.28
    Nov 27, 2023 1.31 0.14 11.97% 1.17 1.31 1.17
    Nov 24, 2023 1.15 -0.01 -0.86% 1.16 1.18 1.13
    Nov 22, 2023 1.08 -0.04 -3.57% 1.12 1.13 1.04
    Nov 21, 2023 1.12 -0.01 -0.88% 1.13 1.17 1.12
    Nov 20, 2023 1.12 0.01 0.90% 1.11 1.16 1.11
    Nov 17, 2023 1.12 -0.01 -0.88% 1.13 1.18 1.10
    Nov 16, 2023 1.12 -0.04 -3.45% 1.16 1.21 1.10
    Nov 15, 2023 1.18 0.02 1.72% 1.16 1.22 1.14
    Nov 14, 2023 1.17 0.05 4.46% 1.12 1.19 1.12
    Nov 13, 2023 1.13 0.00 0.00% 1.13 1.14 1.11
    Nov 10, 2023 1.14 -0.05 -4.20% 1.19 1.19 1.06

    Protara Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, March 6, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Protara Therapeutics Inc Earnings Release
    Q4 2023 Protara Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0
    Total Operating Expense 67.062 47.489 34.444 15.254 21.372
    Selling/General/Admin. Expenses, Total 20.627 26.401 22.462 8.816 9.524
    Research & Development 16.671 21.088 11.982 6.438 11.848
    Operating Income -67.062 -47.489 -34.444 -15.254 -21.372
    Interest Income (Expense), Net Non-Operating 1.11 0.237 0.466 0.262 0.436
    Other, Net 0 0.207
    Net Income Before Taxes -65.952 -47.252 -33.978 -14.992 -20.729
    Net Income After Taxes -65.952 -47.252 -33.978 -14.992 -20.729
    Net Income Before Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
    Net Income -65.952 -47.252 -33.978 -14.992 -20.729
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
    Income Available to Common Incl. Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
    Diluted Net Income -65.952 -47.252 -33.978 -14.992 -20.729
    Diluted Weighted Average Shares 11.2596 11.2326 7.23391 0.49728 0.45256
    Diluted EPS Excluding Extraordinary Items -5.85739 -4.20669 -4.69704 -30.1483 -45.8044
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -3.2359 -4.20669 -4.69704 -30.1483 -45.8044
    Total Extraordinary Items
    Depreciation / Amortization 0.247
    Unusual Expense (Income) 29.517
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 12.14 9.732 39.509 7.974 8.705
    Selling/General/Admin. Expenses, Total 4.893 4.589 5.003 4.508 5.621
    Research & Development 7.247 5.143 4.989 3.466 3.084
    Operating Income -12.14 -9.732 -39.509 -7.974 -8.705
    Interest Income (Expense), Net Non-Operating 0.846 0.687 0.542 0.283 0.166
    Net Income Before Taxes -11.294 -9.045 -38.967 -7.691 -8.539
    Net Income After Taxes -11.294 -9.045 -38.967 -7.691 -8.539
    Net Income Before Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
    Net Income -11.294 -9.045 -38.967 -7.691 -8.539
    Income Available to Common Excl. Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
    Income Available to Common Incl. Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
    Diluted Net Income -11.294 -9.045 -38.967 -7.691 -8.539
    Diluted Weighted Average Shares 11.3078 11.3039 11.2675 11.2655 11.2552
    Diluted EPS Excluding Extraordinary Items -0.99878 -0.80017 -3.45836 -0.68271 -0.75867
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.99878 -0.80017 -0.8387 -0.68271 -0.75867
    Unusual Expense (Income) 29.517
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 86.146 93.112 169.435 6.975 23.236
    Cash and Short Term Investments 84.37 91.229 168.598 6.181 21.867
    Cash & Equivalents 24.127 35.724 168.598 6.181 19.371
    Short Term Investments 60.243 55.505 0 2.496
    Prepaid Expenses 1.163 1.883 0.787 0.744 1.369
    Total Assets 113.29 172.596 203.157 6.975 23.521
    Property/Plant/Equipment, Total - Net 7.869 8.89 2.3 0 0.263
    Property/Plant/Equipment, Total - Gross 8.352 9.126 2.419 0 1.09
    Accumulated Depreciation, Total -0.483 -0.236 -0.119 0 -0.827
    Other Long Term Assets, Total 1.389 1.61 1.905 0 0.022
    Total Current Liabilities 5.74 4.298 2.915 0.583 3.078
    Accounts Payable 1.586 0.954 0.914 0.263 0.441
    Accrued Expenses 4.154 3.344 2.001 0.32 2.637
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 11.207 10.682 3.914 0.583 3.078
    Total Long Term Debt 0 0 0 0 0
    Total Equity 102.083 161.914 199.243 6.392 20.443
    Common Stock 0.011 0.011 0.011 0 0.019
    Additional Paid-In Capital 262.724 256.126 245.992 213.388 209.366
    Retained Earnings (Accumulated Deficit) -159.964 -94.012 -46.76 -225.462 -210.47
    Other Equity, Total -0.688 -0.211 0.003 0.005
    Total Liabilities & Shareholders’ Equity 113.29 172.596 203.157 6.975 23.521
    Total Common Shares Outstanding 11.2674 11.2357 11.2118 0.55763 0.48109
    Redeemable Preferred Stock 18.463 21.523
    Other Current Assets, Total 0.127 0 0.05 0.05
    Preferred Stock - Non Redeemable, Net 0
    Total Preferred Shares Outstanding 0.00803 0.00803 0.00803 0.01895
    Goodwill, Net 0 29.517 29.517
    Other Liabilities, Total 5.467 6.384 0.999
    Long Term Investments 17.886 39.467
    Total Receivables, Net 0.486
    Accounts Receivable - Trade, Net 0.486
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 77.813 84.265 94.616 86.146 98.667
    Cash and Short Term Investments 74.034 80.36 86.61 84.37 96.317
    Cash & Equivalents 33.768 33.978 21.035 24.127 47.498
    Short Term Investments 40.266 46.382 65.575 60.243 48.819
    Prepaid Expenses 3.498 3.56 7.388 1.163 1.97
    Other Current Assets, Total 0.002 0.001 0.127 0.127 0
    Total Assets 88.467 95.141 106.405 113.29 148.591
    Property/Plant/Equipment, Total - Net 6.968 7.25 7.565 7.869 8.168
    Goodwill, Net 0 29.517
    Long Term Investments 0 0 2.893 17.886 10.76
    Other Long Term Assets, Total 3.686 3.626 1.331 1.389 1.479
    Total Current Liabilities 6.775 4.932 6.41 5.74 3.711
    Accounts Payable 2.504 1.852 4.081 1.586 0.456
    Accrued Expenses 4.271 3.08 2.329 4.154 3.255
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 11.511 9.916 11.637 11.207 9.413
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 4.736 4.984 5.227 5.467 5.702
    Total Equity 76.956 85.225 94.768 102.083 139.178
    Common Stock 0.011 0.011 0.011 0.011 0.011
    Additional Paid-In Capital 267.273 265.853 264.235 262.724 261.294
    Retained Earnings (Accumulated Deficit) -190.163 -180.303 -169.009 -159.964 -120.997
    Other Equity, Total -0.165 -0.336 -0.469 -0.688 -1.13
    Total Liabilities & Shareholders’ Equity 88.467 95.141 106.405 113.29 148.591
    Total Common Shares Outstanding 11.3649 11.308 11.3068 11.2674 11.2674
    Total Preferred Shares Outstanding 0.00799 0.00803 0.00803 0.00803 0.00803
    Total Receivables, Net 0.279 0.344 0.491 0.486 0.38
    Accounts Receivable - Trade, Net 0.279 0.344 0.491 0.486 0.38
    Preferred Stock - Non Redeemable, Net 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -65.952 -47.252 -33.978 -14.992 -20.729
    Cash From Operating Activities -26.457 -34.502 -23.407 -15.646 -23.233
    Cash From Operating Activities 0.248 0.117 0.103 0.279 0.115
    Non-Cash Items 38.708 13.149 9.839 0.956 3.402
    Changes in Working Capital 0.539 -0.516 0.629 -1.889 -6.021
    Cash From Investing Activities 14.95 -98.194 2.835 2.484 18.427
    Capital Expenditures -0.12 -0.596 -0.884 -0.016 -0.119
    Other Investing Cash Flow Items, Total 15.07 -97.598 3.719 2.5 18.546
    Cash From Financing Activities -0.09 -0.228 189.401 0 2.985
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net -0.09 -0.228 191.07 0 2.985
    Foreign Exchange Effects 0 0.022
    Net Change in Cash -11.597 -132.924 168.829 -13.162 -1.799
    Cash Interest Paid 0 0 0.034
    Issuance (Retirement) of Debt, Net 0 -1.669
    Cash Taxes Paid 0 0
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -9.045 -65.952 -26.985 -19.294 -10.755
    Cash From Operating Activities -12.888 -26.457 -21.431 -16.084 -10.961
    Cash From Operating Activities 0.077 0.248 0.173 0.109 0.056
    Non-Cash Items 1.845 38.708 7.311 5.26 2.289
    Cash Interest Paid 0
    Changes in Working Capital -5.765 0.539 -1.93 -2.159 -2.551
    Cash From Investing Activities 9.86 14.95 33.295 14.247 0.745
    Capital Expenditures -0.006 -0.12 -0.114 -0.031 -0.011
    Other Investing Cash Flow Items, Total 9.866 15.07 33.409 14.278 0.756
    Cash From Financing Activities -0.064 -0.09 -0.09 -0.072 -0.072
    Issuance (Retirement) of Stock, Net -0.064 -0.09 -0.09 -0.072 -0.072
    Net Change in Cash -3.092 -11.597 11.774 -1.909 -10.288
    Issuance (Retirement) of Debt, Net
    Cash Taxes Paid 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Opaleye Management Inc. Hedge Fund 23.7671 2692594 0 2023-06-30 MED
    Shefferman (Jesse M) Individual Investor 7.1714 812454 -9310 2023-06-27 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 6.8195 772584 -20974 2023-06-30 LOW
    Marshall (Randall S) Individual Investor 5.169 585600 0 2023-04-11 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7745 427612 0 2023-06-30 LOW
    Medical Strategy GmbH Investment Advisor 2.2512 255044 -41727 2023-05-31 MED
    Boxer Capital, L.L.C. Hedge Fund 1.8468 209227 0 2023-06-30 LOW
    Baker Bros. Advisors LP Hedge Fund 1.7625 199671 0 2023-06-30 LOW
    Beshar (Luke M) Individual Investor 1.7477 198000 0 2023-04-11 LOW
    Ikarian Capital LLC Hedge Fund 1.6653 188664 0 2023-06-30 HIGH
    Privium Fund Management (UK) Ltd Investment Advisor 1.0568 119730 0 2023-06-30 HIGH
    Renaissance Technologies LLC Hedge Fund 0.7379 83600 24694 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7363 83420 0 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.5831 66063 -1300 2023-06-30 HIGH
    Bridgeway Capital Management, LLC Investment Advisor 0.5649 64000 0 2023-06-30 MED
    Zummo (Jacqueline) Individual Investor 0.4484 50799 -3824 2023-04-11 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2922 33101 -854 2023-06-30 LOW
    Garceau (Roger J) Individual Investor 0.2913 33000 0 2023-04-11 LOW
    Levy (Richard S) Individual Investor 0.2736 31000 0 2023-04-11 LOW
    Sargen (Gregory P) Individual Investor 0.2736 31000 0 2023-04-11 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Protara Therapeutics, Inc. Company profile

    About Protara Therapeutics Inc

    Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Protara Therapeutics Inc revenues was not reported. Net loss increased 39% to $47.3M. Higher net loss reflects Research and development - other increase of 75% to $19.7M (expense), General and administrative - other increase of 30% to $17.4M (expense), Stock-based Compensation in Research and increase of 90% to $1.4M (expense).

    Industry: Bio Therapeutic Drugs

    345 Park Avenue South
    3rd Floor
    NEW YORK
    NEW YORK 10010
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.63 Price
    -6.480% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    41,828.95 Price
    -4.510% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    1,982.69 Price
    -1.080% 1D Chg, %
    Long position overnight fee -0.0199%
    Short position overnight fee 0.0117%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    16,162.80 Price
    +0.670% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading